Max Robotics — Global Service Robot Directory + US Certification

About

Matthias Kretschmer is a leading figure in the advancement of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC), with a focused expertise in pulmonary radiation oncology and treatment planning standardization. His seminal 2017 planning benchmark study (54 citations) established critical reference data for SBRT of early-stage NSCLC, systematically evaluating interinstitutional and intertechnology variations in dose delivery. Building on this foundational work, Kretschmer’s 2021 research (11 citations) introduced a paradigm-shifting approach by advocating for dose prescription to the mean internal target volume (ITV) dose, directly addressing the substantial variability in dose, fractionation, and normalization across different institutions and SBRT technologies. His work has been instrumental in demonstrating how variations in mean dose within planning target volumes can compromise treatment consistency and clinical outcomes. By proposing standardized prescription methodologies, Kretschmer has significantly improved interinstitutional reproducibility and intertechnology comparability in pulmonary SBRT, directly impacting clinical practice guidelines and treatment planning protocols worldwide. His contributions continue to shape the evolution of precision radiotherapy for lung cancer patients.